- Jardiance (empagliflozin) was associated with a 44 percent reduction in relative risk of hospitalization for heart failure (HHF) compared with commonly used dipeptidyl peptidase-4 inhibitors
- Effect of Jardiance on HHF was consistent in patients with and without established cardiovascular disease
- Findings support data from the landmark EMPA-REG OUTCOME® trial, in which Jardiance reduced the relative risk of HHF by 35 percent in people with type 2 diabetes and established cardiovascular disease
- These early findings from EMPRISE, which will assess the first five years of Jardiance use in the U.S. through 2019, represent data collected between August 2014 and September 2016
PR Newswire
RIDGEFIELD, Conn. and INDIANAPOLIS, Nov. 5, 2018
